Mazumdar T, Anam K, Ali N: A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 2004,22(9–10):1162–1171.Selleck Salubrinal PubMedCrossRef 6. Bhowmick S, Mazumdar T, Ali N: Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun 2009,77(4):1514–1523.PubMedCentralPubMedCrossRef 7. Marrack P, McKee 5-Fluoracil concentration AS, Munks
MW: Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009,9(4):287–293.PubMedCentralPubMedCrossRef 8. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K: Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999,163(8):4481–4488.PubMed 9. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, Naik S: Successful
vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001,19(25–26):3485–3492.PubMedCrossRef 10. Kamil AA, Khalil EA, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, Zijlstra EE, Sacks D, Smith PG, Zicker F, et al.: Alum-precipitated {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003,97(3):365–368.PubMedCrossRef 11. Musa AM, Khalil EAG, Mahgoub FAE, Elgawi SHH, Modabber
F, Elkadaru AEMY, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM, et al.: Immunochemotherapy of persistent post-kata-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Sinomenine Hyg 2008,102(1):58–63.PubMedCrossRef 12. Sun H-X, Xie Y, Ye Y-P: Advances in saponin-based adjuvants. Vaccine 2009,27(12):1787–1796.PubMedCrossRef 13. Santos WR, de Lima VMF, de Souza EP, Bernardo RR, Palatnik M, de Sousa CBP: Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002,21(1–2):30–43.PubMedCrossRef 14. Borja-Cabrera GP, Pontes NNC, da Silva VO, de Souza EP, Santos WR, Gomes EM, Luz KG, Palatnik M, de Sousa CBP: Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002,20(27–28):3277–3284.PubMedCrossRef 15. Santos WR, Aguiar IA, de Souza EP, de Lima VMF, Palatnik M, Palatnik-de-Sousa CB: Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 2003,21(32):4668–4676.PubMedCrossRef 16. Borja-Cabrera GP, Mendes AC, de Souza EP, Okada LYH, Trivellato FAD, Kawasaki JKA, Costa AC, Reis AB, Genaro O, Batista LMM, et al.: Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004,22(17–18):2234–2243.PubMedCrossRef 17.